BSBharath Srinivasan

Bharath Srinivasan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bharath Srinivasan has a total of 180 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Beyond P ‐values and means: Statistical appreciation in the life sciences

    by Bharath Srinivasan

    Statistical literacy is frequently treated in undergraduate and graduate life science training as a technical competency peripheral to experimental practice rather than as a central component of scientific reasoning. This separation is especially problematic in life sciences and related disciplines, where biological variability is intrinsic to living systems and often gives rise to heterogeneous, skewed, multiplicative and non‐normal data. Consequently, the interpretation of biological measurements depends not only on the data themselves but also on how variability, distributions, measurement scale, uncertainty and inference are understood. This perspective argues that stronger statistical appreciation is urgently needed in the life sciences, particularly during early scientific training. Emphasis is placed on the biological origins of variability, the interpretation of distributions, the importance of multiplicative thinking and lognormality, the appropriate use of means, medians, geometric means and logarithmic transformations, and the distinction between variability, uncertainty and effect size. The article further discusses replication, outliers, the limitations of significance testing and why statistical thinking should be embedded within bioscience education as an integral part of scientific reasoning rather than taught as an isolated analytical skill.

  • Open Access

    Protein Pocket Coengagement Prioritizes Drug–Drug Interactions

    by Jeffrey Skolnick, Bharath Srinivasan

    Drug–drug interactions (DDIs) are largely catalogued empirically, with limited structural explanation of why two drugs interact. We asked whether a purely structural mechanism — competing or cooperating engagement of the same protein pocket — is sufficient to recover documented DDIs without any training on clinical interaction labels. Using composite protein multiple-ligand (COLIG) assignments, which classify co-bound ligand pairs as attractive or repulsive, we scored 21,945 pairs of 210 drugs by predicted engagement of each protein’s top-ranked pocket. Confidence-summed COLIG ranking achieved top-5% precision of 49.3% against DDInter and 25.1% against KEGG, versus background prevalences of 29.6% and 14.7%, respectively; pooled top-pocket engagement reached 50.3% DDInter precision. These results support pocket-based DDI screening and class-dependent hypotheses about direct and noncontact ligand engagement, while leaving causal mechanisms to be established.

  • Open Access

    The human metabolite–protein interactome reveals a global layer of cellular coordination

    by Jeffrey Skolnick, Bharath Srinivasan

    Metabolites are substrates, products, cofactors, and regulators, but protein–protein interaction networks do not represent their potential to organize proteins across conventional pathway boundaries. Using the LIGMAP virtual-screening algorithm, we mapped 308 human metabolite codes to pockets in monomers, dimer interfaces, and non-interface sites in dimers and represented attractive or repulsive COLIG states involving pairs of metabolites in the same pocket. On a fixed cohort of 3,938 proteins, the mean coverage of 104 strict non-enzyme pathways was 44.6% for LIGMAP, 70.1% for STRING, and 82.5% for STRING+LIGMAP; the union placed 86.3% of eligible proteins in the largest connected component and 95.1% in the two largest components. STRING+LIGMAP protein coverage was 88.0% for 68 enzyme-only pathways and 88.9% for 1,283 mixed pathways. In pathway-held-out, degree-matched prediction, adding LIGMAP to degree plus STRING increased the mean area under the precision–recall curve from 0.651 to 0.660 (paired P = 0.024); adding BioLiP2 increased it to 0.663 (paired P = 0.005). Ancient-only and non-ancient-only subnetworks were each globally connected; ancient features were denser, whereas non-ancient features covered more proteins and pathways. At the full 5,426-protein scale, retaining only features assigned to 2–100 proteins recovered 698 of 1,691 strict non-enzyme reference edges (41.3%) and exceeded both protein-label and exact bipartite degree-preserving nulls. Uncapped recovery approached saturation and lost identity-selective enrichment. Experimentally established metabolite-dependent complexes validate the local mechanism independently of LIGMAP; LIGMAP fully recovered two of seven stringent direct mechanisms and all three broader serial axes examined. Our findings reveal a global metabolite-mediated architecture with the capacity to coordinate proteins across otherwise distinct cellular systems.

  • Open Access

    Metabolites form a globally connected chemical network across protein families

    by Jeffrey Skolnick, Bharath Srinivasan

    Metabolites are generally viewed as substrates, products, cofactors, or regulators of individual proteins, whereas metabolites recurring across many protein families are often regarded as promiscuous binders. Here, we analyzed 989,058 BioLiP2 protein - ligand binding sites and assigned 929,546 sites to ECOD v295 homologous groups to quantify ligand specificity, cross-fold scatter, structural breadth, and metabolite-mediated connectivity across protein-family space. Many ancient metabolites preferentially occupied cognate structural groups, demonstrating that broad evolutionary reuse can coexist with local structural discrimination. After excluding elemental metals, BioLiP potential-artifact/dual-use ligands, and metabolites containing fewer than six heavy atoms, 32 ancient metabolites occupied a mean of 185.38 ECOD F-groups per metabolite, compared with 6.32 F-groups for 2,540 mapped filtered non-ancient metabolites - a 29.35-fold enrichment (bootstrap 95% CI, 18.66 - 43.46). The complete 40-ancient-metabolite network connected all 6,798 associated F-groups into a single giant connected component (GCC). Even after stringent filtering, all 3,135 ancient-metabolite-associated F-groups remained in one GCC. Degree-preserving configuration-model randomizations and maximum-degree capping showed that this connectivity follows from the broad, recurrent distribution of metabolite binding rather than dependence on a few extreme hubs or a specialized higher-order topology. Differences between ancient and filtered non-ancient networks were not explained by metabolite size, whereas generic crystallization additives preferentially occupied smaller pockets. These results indicate that a limited ancient chemical repertoire established a globally connected protein-family architecture that subsequent metabolite diversification expanded while preserving its basic organization.

  • Open Access

    Protein-ligand binding kinetics are primarily controlled by the protein, not the ligand

    by Bharath Srinivasan, Ana Corrionero, Marco Barone, Patricia Alfonso, Niall Prendiville, Tatiana Cazorla, Anza Suneer Rahiyanath, Adrian Whitty, Peter Tonge

    SUMMARY: Protein–ligand interactions underpin biological regulation and drug action, with both binding affinity and binding kinetics shaping functional outcomes. By analysing kinetic data for 4,311 protein-small-molecule pairs, we find that when association occurs below the diffusion-controlled limit, the rates of ligand association ( k on ) and dissociation ( k off ) are primarily determined by how the initial encounter complex reorganizes into the final bound state, and that this reorganization is governed chiefly by the intrinsic dynamic properties of the protein rather than by structural features of the ligand. Counterintuitively, therefore, k off exhibits minimal dependence on ligand structure, so that dissociation proceeds through protein-gated conformational transitions rather than through direct rupture of protein–ligand contacts. This mechanistic behaviour stands in marked contrast to that for protein–protein complexes, based on an analysis of 1,561 interactions. Together, these findings challenge prevailing assumptions regarding the molecular determinants of small-molecule binding kinetics, and have broad implications for rationally modulating protein–ligand interactions and drug-target residence times.

  • Open Access

    GlueFinder: A Data-Driven Framework for the Rational Discovery of Molecular Glues

    by Jeffrey Skolnick, Bharath Srinivasan, Hongyi Zhou

    Molecular glues drive targeted protein degradation by stabilizing ternary complexes between proteins of interest and E3 ubiquitin ligases, but their rational design has lagged due to a limited understanding of the rules for interface recognition and an overreliance on a few ligases (e.g., VHL or Cereblon). We introduce GlueFinder, a systematic, unbiased platform that leverages structural bioinformatics to mine the Protein Data Bank for ligand-binding pockets adjacent to the protein interface which are ligandable sites that can nucleate glue-mediated complex formation. After validating its performance on a benchmark of experimentally solved dimeric structures with known and predicted glues, we applied GlueFinder to three therapeutically important targets, EGFR, HER2, and KRAS, and predicted candidate glues that recruit 24, 111, and 148 distinct E3 ligases to these targets, respectively. We further demonstrate that GlueFinder can promote the formation of non-native EGFR complexes with a variety of diverse proteins, possibly enabling ternary assemblies that would not form on their own. These results establish a general, computation-guided experimental prioritization strategy for molecular glue discovery that decouples design from legacy degrader scaffolds and specific ligase dependencies, expands the usable E3 ligase repertoire, and enables rational targeting of interfacial binding pockets.


  • Modulating the Binding Kinetics of Bruton’s Tyrosine Kinase Inhibitors through Transition-State Effects

    by Eduardo Bravo, Yong Li, David Yin-Wei Lin, Bharath Srinivasan, Marco Barone, Stan Xiaogang Li, Francesca DelloRusso, Anza Suneer Rahiyanath, Ana Corrionero, Patricia Alfonso, et al.

    Optimization exercises strive toward increasing the efficacy and selectivity of small molecules toward the target of interest while simultaneously phasing out design elements that lead to off-target interactions. Given the nonequilibrium nature of biological systems, greater reliance should be placed on engineering kinetic selectivity in addition to equilibrium thermodynamic selectivity; however, the rational design of kinetic selectivity is a challenging endeavor. This study presents a systematic knowledge-based approach to the design of inhibitors that vary in their binding kinetics for Bruton's tyrosine kinase (BTK), a target for treating B-cell malignancies and autoimmune diseases. A detailed kinetic assessment was performed on existing BTK inhibitors, which, together with structural studies, provided critical insights into BTK-inhibitor interactions that control the kinetics of enzyme inhibition. Subsequently, a series of pyrazolopyrimidines was designed with the objective of modifying interactions between the inhibitor and the regulatory (R) spine in the kinase back pocket, which were hypothesized to modulate the stability of the transition state on the binding reaction coordinate. This resulted in the development of BTK inhibitors with extended residence time in which the variation in kon and koff was uncoupled from equilibrium thermodynamic affinity.